TCRT
Alaunos Therapeutics, Inc.
+0.03 (+2.34%)1.31USD11.2K成交股數3.3M市值–本益比(近四季)1109.3股價營收比–營收年增(近四季)–下次財報
內部人交易 SEC Form 4 · 董事、高階主管與持股 10% 以上股東 · 交易後兩個營業日內申報
買賣點與股價近一年
● 公開市場買進 · ● 公開市場賣出 · 空心 = 10b5-1 預設計畫(事先排程,不代表當下看法)。近一年,只畫 P / S 兩種代碼。
統計
| 近 90 天 買進筆數 · 金額 · 人數 | 0 · 0 · 0 |
|---|---|
| 近 90 天 賣出筆數 · 金額 · 人數 | 0 · 0 · 0 |
| 其中 10b5-1 計畫賣出 | 0 筆 |
| 近 180 天 買進 · 賣出金額 | 0 · 0 |
| 近 180 天 淨額 | 0 |
公開市場買進(P)是內部人自掏腰包,通常比賣出更有資訊含量 —— 賣出的理由很多(繳稅、分散、買房),買進的理由只有一個。
10b5-1 是事先排定的交易計畫,執行時點不反映當下看法。獲配股票(A)、繳稅扣股(F)、選擇權執行(M)是薪酬流程,不是意見。
| 交易日 | 申報日 | 申報人 | 職稱 | 代碼 | 股數 | 價格 | 金額 | 交易後持股 | 原件 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | 08-11 | Weis Holger | CEO | A 獲配股票 | 4.4K | 2.01 | 9K | 25.5K | SEC |
| 2026-07-23 | 07-27 | Vieser Jaime | Director | A 獲配股票 | 8.8K | 1.92 | 17K | 47.6K | SEC |
| 2026-07-23 | 07-27 | Weis Holger | CEO | A 獲配股票 | 4.6K | 1.92 | 9K | 21.1K | SEC |
| 2026-07-23 | 07-27 | Jerman Michael Allen | Director | A 獲配股票 | 8.1K | 1.92 | 16K | 23.8K | SEC |
| 2026-07-23 | 07-27 | Postma Robert W | Director | A 獲配股票 | 8.5K | 1.92 | 16K | 58.6K | SEC |
| 2026-06-30 | 07-02 | Weis Holger | Chief Executive Officer | A 獲配股票 | 3.9K | 2.26 | 9K | 16.6K | SEC |
| 2026-06-12 | 06-17 | Weis Holger | Chief Executive Officer | A 獲配股票 | 7.8K | 2.26 | 18K | 12.7K | SEC |
| 2026-05-22 | 05-27 | Weis Holger | Chief Executive Officer | A 獲配股票 | 3.7K | 2.37 | 9K | 4.9K | SEC |
| 2026-04-29 | 05-01 | Jerman Michael Allen | Director | A 獲配股票 | 6.0K | 2.59 | 16K | 15.6K | SEC |
| 2026-04-29 | 05-01 | Vieser Jaime | Director | A 獲配股票 | 6.5K | 2.59 | 17K | 38.9K | SEC |
| 2026-04-29 | 05-01 | Postma Robert W | Director | A 獲配股票 | 6.3K | 2.59 | 16K | 50.1K | SEC |
| 2026-01-12 | 01-15 | Postma Robert W | Director | A 獲配股票 | 5.6K | 2.89 | 16K | 43.9K | SEC |
| 2026-01-12 | 01-15 | Vieser Jaime | Director | A 獲配股票 | 5.8K | 2.89 | 17K | 32.3K | SEC |
| 2026-01-12 | 01-15 | Jerman Michael Allen | Director | A 獲配股票 | 5.4K | 2.89 | 16K | 9.6K | SEC |
| 2025-11-21 | 11-26 | Postma Robert W | Director | A 獲配股票 | 5.1K | 3.16 | 16K | 38.3K | SEC |
| 2025-11-21 | 11-26 | Jerman Michael Allen | Director | A 獲配股票 | 4.2K | 3.16 | 13K | 4.2K | SEC |
| 2025-11-21 | 11-26 | Vieser Jaime | Director | A 獲配股票 | 5.3K | 3.16 | 17K | 26.5K | SEC |
| 2025-08-18 | 08-20 | Groenewald Ferdinand | Vice President of Finance | A 獲配股票 | 10.8K | – | – | 10.8K | SEC |
| 2025-07-03 | 07-07 | Postma Robert W | Director | A 獲配股票 | 4.0K | – | – | 33.1K | SEC |
| 2025-07-03 | 07-07 | Vieser Jaime | Director | A 獲配股票 | 3.4K | – | – | 21.2K | SEC |
| 2025-04-13 | 06-26 | Postma Robert W | Director | A 獲配股票 | 20.8K | 2.92 | 61K | 29.1K | SEC |
| 2025-04-13 | 04-15 | Vieser Jaime | Director | A 獲配股票 | 17.5K | – | – | 43.4K | SEC |
| 2025-04-13 | 04-15 | Postma Robert W | Director | A 獲配股票 | 20.8K | 2.92 | 61K | 29.1K | SEC |
| 2024-12-31 | 01-03 | Vieser Jaime | Director | S 公開市場賣出 | 818 | 2.00 | 2K | 25.9K | SEC |
| 2024-12-31 | 01-03 | Vieser Jaime | Director | S 公開市場賣出 | 2.2K | 2.01 | 4K | 26.7K | SEC |
| 2023-09-01 | 09-05 | Boyle Kevin S. Sr. | Chief Executive Officer | S 公開市場賣出(10b5-1) | 68.0K | 0.14 | 10K | 798K | SEC |
| 2022-11-29 | 12-01 | Postma Robert W | Director | P 公開市場買進 | 750K | 0.65 | 488K | 5.0M | SEC |
| 2022-11-29 | 12-01 | Vieser Jaime | Director | P 公開市場買進 | 1.3M | 0.65 | 813K | 1.3M | SEC |
| 2022-08-30 | 09-01 | Boyle Kevin S. Sr. | Chief Executive Officer | F 繳稅扣股 | 18.8K | 2.41 | 45K | 866K | SEC |
| 2022-06-22 | 06-24 | Bowden Christopher | Director | A 獲配股票 | 40.0K | – | – | 44.2K | SEC |
| 2022-06-22 | 06-24 | Weis Holger | Director | A 獲配股票 | 40.0K | – | – | 160K | SEC |
| 2022-06-22 | 06-24 | Postma Robert W | Director | A 獲配股票 | 40.0K | – | – | 1.2M | SEC |
| 2022-06-22 | 06-24 | Postma Robert W | Director | A 獲配股票 | 40.0K | – | – | 1.2M | SEC |
| 2022-06-22 | 06-24 | Huang James | Director | A 獲配股票 | 80.0K | – | – | 188K | SEC |
| 2022-06-22 | 06-24 | Thistle Mary | Director | A 獲配股票 | 40.0K | – | – | 45.0K | SEC |
| 2022-06-22 | 06-24 | Vieser Jaime | Director | A 獲配股票 | 40.0K | – | – | 745K | SEC |
| 2022-06-22 | 06-24 | Huang James | Director | A 獲配股票 | 80.0K | – | – | 188K | SEC |
| 2022-06-22 | 06-24 | Thistle Mary | Director | A 獲配股票 | 40.0K | – | – | 45.0K | SEC |
| 2021-12-22 | 12-27 | De Groot Eleanor | EVP, Operations | S 公開市場賣出 | 20.1K | 1.27 | 26K | 237K | SEC |
| 2021-11-17 | 11-17 | Boyle Kevin S. Sr. | Chief Executive Officer | P 公開市場買進 | 9.1K | 1.40 | 13K | 885K | SEC |
| 2021-11-16 | 11-17 | Boyle Kevin S. Sr. | Chief Executive Officer | P 公開市場買進 | 884 | 1.40 | 1K | 876K | SEC |
| 2021-09-29 | 10-04 | Vieser Jaime | Director | P 公開市場買進 | 100K | 1.91 | 191K | 705K | SEC |
| 2021-09-02 | 09-03 | Hagen Heidi | Director | P 公開市場買進 | 23.8K | 1.76 | 42K | 146K | SEC |
| 2021-09-02 | 09-03 | Postma Robert W | Director | P 公開市場買進 | 54.5K | 1.73 | 94K | 4.3M | SEC |
| 2021-09-02 | 09-03 | Postma Robert W | Director | P 公開市場買進 | 20.5K | 1.73 | 35K | 1.2M | SEC |
| 2021-09-01 | 09-03 | Huang James | Director | P 公開市場買進 | 100K | 1.71 | 171K | 108K | SEC |
| 2021-09-01 | 09-03 | Weis Holger | Director | P 公開市場買進 | 50.0K | 1.83 | 92K | 120K | SEC |
| 2021-08-30 | 08-31 | Boyle Kevin S. Sr. | Chief Executive Officer | A 獲配股票 | 875K | – | – | 875K | SEC |
| 2021-05-17 | 05-19 | Baffa Raffaele | Chief Medical Officer | A 獲配股票 | 80.6K | – | – | 281K | SEC |
| 2021-03-04 | 05-06 | Bowden Christopher | Director | A 獲配股票 | 4.2K | – | – | 4.2K | SEC |
| 2021-03-04 | 05-06 | Huang James | Director | A 獲配股票 | 8.3K | – | – | 8.3K | SEC |
| 2021-03-04 | 05-06 | Weis Holger | Director | A 獲配股票 | 4.2K | – | – | 70.2K | SEC |
| 2021-03-04 | 05-06 | Vieser Jaime | Director | A 獲配股票 | 4.2K | – | – | 605K | SEC |
| 2021-03-04 | 05-06 | Thistle Mary | Director | A 獲配股票 | 5.0K | – | – | 5.0K | SEC |
| 2021-03-04 | 05-06 | Postma Robert W | Director | A 獲配股票 | 2.5K | – | – | 1.2M | SEC |
| 2021-03-04 | 05-06 | BUCHI J KEVIN | Director | A 獲配股票 | 4.2K | – | – | 4.2K | SEC |
| 2021-03-04 | 03-08 | Hagen Heidi | Interim CEO | A 獲配股票 | 90.0K | – | – | 122K | SEC |
| 2021-03-04 | 03-08 | Buck Jill | EVP, GM Gene Therapy | A 獲配股票 | 31.5K | – | – | 231K | SEC |
| 2021-03-04 | 03-08 | De Groot Eleanor | EVP, GM Cell Therapy | A 獲配股票 | 50.8K | – | – | 257K | SEC |
| 2021-03-04 | 03-08 | Hadfield Robert | Chief Legal Officer and Sec. | A 獲配股票 | 43.5K | – | – | 177K | SEC |
| 2021-01-08 | 01-12 | Buck Jill | EVP, GM Gene Therapy | S 公開市場賣出 | 27.9K | 3.12 | 87K | 200K | SEC |
| 2021-01-08 | 01-12 | Lafond Kevin G | SVP, Treasurer & CAO | S 公開市場賣出 | 18.0K | 3.09 | 56K | 64.0K | SEC |
| 2021-01-08 | 01-12 | Hadfield Robert | General Counsel and Secretary | S 公開市場賣出 | 26.5K | 3.12 | 83K | 133K | SEC |
| 2021-01-04 | 01-06 | Cooper Laurence James Neil | President and CEO | S 公開市場賣出 | 106K | 2.71 | 286K | 1.8M | SEC |
| 2021-01-04 | 01-06 | De Groot Eleanor | EVP, GM Cell Therapy | S 公開市場賣出 | 21.6K | 2.72 | 59K | 206K | SEC |
| 2020-01-29 | 01-31 | Buck Jill | EVP, GM Gene Therapy | A 獲配股票 | 53.7K | – | – | 227K | SEC |
| 2020-01-29 | 01-31 | Shukla Sath | EVP, Chief Financial Officer | A 獲配股票 | 80.5K | – | – | 80.5K | SEC |
| 2020-01-29 | 01-31 | De Groot Eleanor | EVP, GM Cell Therapy | A 獲配股票 | 53.7K | – | – | 228K | SEC |
| 2020-01-29 | 01-31 | Cooper Laurence James Neil | Chief Executive Officer | A 獲配股票 | 172K | – | – | 1.9M | SEC |
| 2020-01-29 | 01-31 | MAUNEY DAVID M MD | President | A 獲配股票 | 80.5K | – | – | 276K | SEC |
| 2020-01-29 | 01-31 | Lafond Kevin G | SVP, Treasurer & CAO | A 獲配股票 | 18.0K | – | – | 82.0K | SEC |
| 2020-01-29 | 01-31 | Hadfield Robert | General Counsel and Secretary | A 獲配股票 | 59.1K | – | – | 160K | SEC |
| 2020-01-02 | 01-03 | Lafond Kevin G | SVP, Treasurer & CAO | S 公開市場賣出 | 21.6K | 4.55 | 98K | 64.0K | SEC |
| 2020-01-02 | 01-03 | Hadfield Robert | General Counsel and Secretary | S 公開市場賣出 | 16.9K | 4.55 | 77K | 101K | SEC |
| 2020-01-02 | 01-03 | De Groot Eleanor | EVP, GM Cell Therapy | S 公開市場賣出 | 24.9K | 4.55 | 113K | 174K | SEC |
| 2020-01-02 | 01-03 | Buck Jill | EVP, GM Gene Therapy | S 公開市場賣出 | 27.9K | 4.55 | 127K | 174K | SEC |
| 2020-01-02 | 01-03 | MAUNEY DAVID M MD | President | S 公開市場賣出 | 22.4K | 4.55 | 102K | 195K | SEC |
| 2019-12-31 | 01-03 | Hagen Heidi | Director | A 獲配股票 | 31.8K | – | – | 32.1K | SEC |
| 2019-12-31 | 01-03 | Ezickson Elan | Director | F 繳稅扣股 | 40.1K | 4.72 | 189K | 71.9K | SEC |
| 2019-12-31 | 01-03 | Ezickson Elan | Director | A 獲配股票 | 31.8K | – | – | 112K | SEC |
機構持股(13F) 管理規模 1 億美元以上的機構,每季末後 45 天內申報 ·
前 25 大持有機構季末市值 · 與前一季股數比較
| 機構 | 持股 | 季末市值 | 股數季變化 | 動作 |
|---|---|---|---|---|
| 沒有 13F 資料。 | ||||
持有機構數近 12 季
13F 只申報多頭部位(含可轉債與選擇權,選擇權這裡已排除),不申報放空,也不申報 1 億美元以下的機構。同一集團多個申報主體會各算一家。
放空餘額 FINRA 每月兩次(15 日與月底結算)· 最新 2026-08-31
空單佔流通股近 13 個月
FINRA 每月兩次結算的空單餘額佔流通股數的比例,近 13 個月。滑到柱子看股數與回補天數。
最新一期
| 空單股數 | 5.7K |
|---|---|
| 與上期比 | -54.4% |
| 佔流通股數 | 0.22% |
| 日均成交量 | 16.4K |
| 回補天數 | 1.0 天 |
空單佔比 10% 以上算高、20% 以上算很高(這是通行的說法,不是本站的判斷)。回補天數 = 空單 ÷ 日均量,天數愈長,空方要出場時愈容易推升股價。
放空餘額是「有人借股票賣掉還沒還」的存量,不代表看空的人正在加碼;避險基金做多空配對時也會產生空單。
| 結算日 | 空單股數 | 與上期比 | 佔流通股 | 日均量 | 回補天數 |
|---|---|---|---|---|---|
| 2026-08-31 | 5.7K | -54.4% | 0.22% | 16.4K | 1.0 |
| 2026-08-14 | 12.5K | +28.0% | 0.49% | 8.1K | 1.6 |
| 2026-07-31 | 9.8K | -26.6% | 0.38% | 10.1K | 1.0 |
| 2026-07-15 | 13.3K | -9.2% | 0.52% | 15.6K | 1.0 |
| 2026-06-30 | 14.7K | +26.4% | 0.58% | 13.9K | 1.1 |
| 2026-06-15 | 11.6K | -16.5% | 0.46% | 21.8K | 1.0 |
| 2026-05-29 | 13.9K | +76.1% | 0.55% | 24.0K | 1.0 |
| 2026-05-15 | 7.9K | -9.4% | 0.31% | 8.0K | 1.0 |
| 2026-04-30 | 8.7K | -29.6% | 0.34% | 13.5K | 1.0 |
| 2026-04-15 | 12.4K | -12.6% | 0.49% | 16.1K | 1.0 |
| 2026-03-31 | 14.2K | +4.7% | 0.56% | 19.3K | 1.0 |
| 2026-03-13 | 13.5K | -60.5% | 0.53% | 17.4K | 1.0 |
| 2026-02-27 | 34.3K | -10.4% | 1.35% | 11.7K | 2.9 |
| 2026-02-13 | 38.2K | -14.3% | 1.50% | 11.8K | 3.2 |
| 2026-01-30 | 44.6K | -14.7% | 1.76% | 15.8K | 2.8 |
| 2026-01-15 | 52.3K | +38.0% | 2.06% | 41.8K | 1.3 |
| 2025-12-31 | 37.9K | -14.5% | 1.49% | 58.1K | 1.0 |
| 2025-12-15 | 44.3K | -36.7% | 1.74% | 68.8K | 1.0 |
| 2025-11-28 | 70.0K | -2.6% | 2.75% | 63.6K | 1.1 |
| 2025-11-14 | 71.9K | -12.0% | 2.83% | 37.4K | 1.9 |
| 2025-10-31 | 81.7K | -25.1% | 3.21% | 46.5K | 1.8 |
| 2025-10-15 | 109K | +79.1% | 4.29% | 2.3M | 1.0 |
| 2025-09-30 | 60.8K | -15.4% | 2.39% | 22.4K | 2.7 |
| 2025-09-15 | 71.9K | -28.4% | 2.83% | 42.7K | 1.7 |
| 2025-08-29 | 101K | +731.1% | 3.96% | 634K | 1.0 |
| 2025-08-15 | 12.1K | -56.1% | 0.48% | 46.1K | 1.0 |